Induction of apoptosis in HL-60 cells by bortezomib alone or in combination with harringtonine in vitro.
- Author:
Qi-Xin SUN
1
;
Fan-Yi MENG
;
Yun-Bi FU
;
Li LI
Author Information
1. Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
pharmacology;
Apoptosis;
drug effects;
Boronic Acids;
pharmacology;
Bortezomib;
Cell Proliferation;
drug effects;
Dose-Response Relationship, Drug;
Drug Synergism;
HL-60 Cells;
Harringtonines;
pharmacology;
Humans;
Pyrazines;
pharmacology
- From:
Journal of Experimental Hematology
2007;15(2):233-236
- CountryChina
- Language:Chinese
-
Abstract:
The aim of this study was to investigate the effect of bortezomib alone and in combination with harringtonine on apoptosis of HL-60 cells. HL-60 cells were treated with bortezomib, harringtonine in different concentrations for 12 - 48 hours. Cell proliferation was analyzed by MTT assay; the apoptosis of HL-60 cells was observed by DNA gel electrophoresis, fluorescence microscopy and flow cytometry. The results showed that 10 - 50 nmol/L bortezomib could effectively inhibit HL-60 cell proliferation, and induced its apoptosis. After treating for 12 hours, 10 nmol/L bortezomib could trigger cells apoptosis. With time prolongation or dose increase, HL-60 cell apoptotic rate significantly increased. Furthermore, co-administration of bortezomib (10 nmol/L) with harringtonine (30 nmol/L) resulted in a higher cell apoptotic rate when compared with that induced by those agents used alone. It is concluded that the bortezomib can induce HL-60 cells apoptosis in a time-and-dose-dependent manner and synergistic effectiveness can be found when bortezomib combined with harringtonine.
